“A new hope for infants and high-risk adults against RSV!”
What is Clesrovimab?
A monoclonal antibody that prevents RSV infection
Works by neutralizing the virus before it causes severe illness
Mechanism of action - Clesrovimab binds to a conserved epitope on the antigenic site IV on the RSV fusion (F) protein. This inhibits fusion of the viral membrane with the host cell membrane and prevents viral entry and subsequent infection.
Side effects - Injection site erythema and swelling, Rash
Why it’s important:
RSV can cause severe respiratory illness in infants and older adults
Early trials show promising protection and fewer hospitalizations
Affordable and easy to administer
Could this be a game-changer in preventing respiratory infections?
This FDA approval of clesrovimab (Enflonsia) is a significant step forward in protecting infants from RSV, offering an effective, single-dose preventive option that could substantially reduce hospitalizations during the first RSV season.
Absolutely! A single-dose option like clesrovimab can be a game-changer in protecting infants from severe RSV and easing the burden on healthcare systems.
DrAnshul, this is such a promising update! Clesrovimab seems like a real game-changer, especially for infants and high-risk adults who can suffer severe RSV complications.
I like how you highlighted the mechanism — blocking viral fusion at the antigenic site IV is such a precise strategy. Makes me wonder if this could set the stage for more monoclonal antibodies targeting respiratory viruses.
Would love to hear your thoughts: could this shift the way we approach RSV prevention globally, beyond just high-risk gro
A total of 3614 infants received an injection: 2412 infants received clesrovimab, and 1202 infants received placebo.
Through day 150 after injection, RSV-associated medically attended lower respiratory infection occurred in 60 of 2398 infants in the clesrovimab group (incidence rate over 5-month period, 2.6%)
74 of 1201 infants in the placebo group (incidence rate over 5-month period, 6.5%), for an efficacy of 60.4% .
RSV-associated hospitalization within 150 days was reported in 9 of 2398 infants in the clesrovimab group and in 28 of 1201 infants in the placebo group.
Serious adverse events were reported in 278 of 2409 infants (11.5%) in the clesrovimab group and 149 of 1202 infants (12.4%) in the placebo group.
Exactly! Nevethaa🌟 Clesrovimab’s targeted mechanism is indeed a precise and promising approach. It could potentially reshape RSV prevention, especially if combined with broader public health strategies and early immunization programs.
Quick question for you, Being a Pharma D. Graduate do you think monoclonal antibodies like this could eventually be used for routine RSV prevention in all infants, or will it remain focused on high-risk groups?
